Predictive Oncology Files 8-K with Corporate Updates
Ticker: AGPU · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1446159
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
Predictive Oncology filed an 8-K on Dec 9th, likely with corporate or financial updates. Keep an eye on this.
AI Summary
Predictive Oncology Inc. filed an 8-K on December 11, 2025, reporting events as of December 9, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws and includes Financial Statements and Exhibits. The company, formerly known as Skyline Medical Inc., is incorporated in Delaware and has its principal business address in Pittsburgh, PA.
Why It Matters
This filing signals potential changes in the company's governance or financial structure, which could impact its strategic direction and investor outlook.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting corporate actions and financial statements, not indicating immediate financial distress or significant negative events.
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- Skyline Medical Inc. (company) — Former company name
- December 9, 2025 (date) — Earliest event reported date
- December 11, 2025 (date) — Filing date
- Pittsburgh, PA (location) — Business address
FAQ
What specific amendments were made to the Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What is the nature of the Financial Statements and Exhibits being filed?
The filing states that Financial Statements and Exhibits are included, but their specific content is not detailed in the provided text.
When was the company formerly known as Skyline Medical Inc.?
The company was formerly known as Skyline Medical Inc. prior to a name change on August 7, 2013.
What is the Commission File Number for Predictive Oncology Inc.?
The Commission File Number for Predictive Oncology Inc. is 001-36790.
What is the I.R.S. Employer Identification No. for Predictive Oncology Inc.?
The I.R.S. Employer Identification No. for Predictive Oncology Inc. is 33-1007393.
Filing Stats: 674 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2025-12-10 17:45:43
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market
Filing Documents
- f8k_121025.htm (8-K) — 24KB
- exh_31.htm (EX-3.1) — 8KB
- exh_32.htm (EX-3.2) — 60KB
- 0001171843-25-007861.txt ( ) — 273KB
- poai-20251209.xsd (EX-101.SCH) — 3KB
- poai-20251209_lab.xml (EX-101.LAB) — 33KB
- poai-20251209_pre.xml (EX-101.PRE) — 22KB
- f8k_121025_htm.xml (XML) — 4KB
03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Years
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Years. On December 9, 2025, Predictive Oncology Inc. (the " Company ") filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company's Certificate of Incorporation to change its corporate name from Predictive Oncology Inc. to Axe Compute Inc. (the " Name Change "), effective December 11, 2025. The Board of Directors of the Company (the " Board ") approved the Name Change pursuant to Section 242 of the General Corporation Law of the State of Delaware (the " DGCL "). No stockholder approval was required under Section 242(b)(1) of the DGCL. A copy of the Certificate of Amendment to the Certificate of Incorporation is attached as Exhibit 3.1 hereto and incorporated by reference. In connection with the Name Change, the Board approved and adopted the Third Amended and Restated Bylaws, also effective on December 11, 2025 (the " A&R Bylaws "), to reflect the corporate name Axe Compute Inc. and to integrate prior amendments to the Company's bylaws, dated September 9, 2022 (as amended to date, the " Bylaws "). No other substantive changes were made to the Bylaws. A copy of the A&R Bylaws is attached as Exhibit 3.2 hereto and incorporated by reference. As a result of the Name Change, the Company's common stock will begin trading on The Nasdaq Stock Market LLC under the new ticker symbol "AGPU," effective on or about December 12, 2025. No change will be made to the CUSIP number for the Company's common stock in connection with the Name Change. Outstanding stock certificates for shares of the Company are not affected by the Name Change; they continue to be valid and need not be exchanged.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to the Certificate of Incorporation 3.2 Third Amended and Restated Bylaws 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY INC. Date: December 10, 2025 By: /s/ Josh Blacher Name: Josh Blacher Title: Chief Financial Officer